ArticleClinical and experimental vaccine research2025
Autoimmune manifestations recorded after SARS-CoV-2 vaccination.
Article in Clinical and experimental vaccine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changes in ANA Positivity Following SARS-CoV-2 Outbreak in Lombardy Region, Italy.Journal of medical virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To present, to the best of our knowledge, the largest African case series of autoimmune manifestations (AIM) after coronavirus disease 2019 (COVID-19) vaccination. Materials and Methods: Cases were collected consecutively from March 2021 to December 2022 from the various departments of the university teaching hospital of Monastir. Autoimmunity biomarkers were investigated mainly in the laboratory of immunology of the same hospital. Anti-nuclear antibody (ANA) screening was performed by indirect immunofluorescence on Results: This case series reports 14 patients (age range, 34-69 years; sex ratio, 1:1) who developed AIM after COVID-19 vaccination with the Pfizer BioNTech, Oxford-AstraZeneca, Johnson & Johnson's Janssen, or Sputnik V vaccines between March 2021 and December 2022. The clinical onset occurred 1 week to 2 months after the last administrated dose. Immunological evaluation revealed positive ANA in 13 cases (titer 1/180 to 1/3,200). Autoantibodies typing revealed anti-mitochondria type 2 in 4 cases, anti-SSA in 3 cases, and anti-DFS70 in 2 cases. Nine patients received specific treatments for diagnosed autoimmune diseases (AID), whereas the others showed non-specific immune stimulation, reactive arthritis, myositis, and cerebral venous thrombosis, which improved with symptomatic treatment. Conclusion: This series suggests a link between severe acute respiratory syndrome coronavirus 2 vaccination and triggered or revealed AID or AIM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.